Skip to main content

Table 1 Patient, donor and transplants characteristics

From: Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies

Patient characteristics

Intensified myeloablative conditioning (n = 81)

Standard myeloablative conditioning (n = 104)

P-value

Female/Male

31(38.3%)/50(61.7%)

41(39.4%)/63(60.6%)

NS

Median age, years (range)

26(14–54)

28(12–63)

NS

Disease

   

  ALL

42 (51.85%)

23 (22.1%)

P<0.001

  AML

17 (21.0%)

43(41.4%)

 

  ALAL

12 (14.8%)

12 (11.5%)

 

  CML

6 (7.4%)

22 (21.2%)

 

  HD/NHL

3(3.7%)

2 (1.9%)

 

  MDS

0 (0%)

2 (1.9%)

 

  BPDCN

1 (1.25%)

0 (0%)

 

Disease status at the time of transplants

   

  CR (including CML-CP)

31 (38.3%)

94 (90.4%)

P<0.001

  NR (including CML-AP and BC)

50 (61.7%)

10 (9.6%)

 

EBV serostatus

   

  D-/R-

15(18.5 %)

21(20.2 %)

NS

  D+/R-

23(28.4%)

27(26.0%)

 

  D-/R+

16(19.8%)

22(21.1%)

 

  D+/R+

27(33.3%)

34(32.7%)

 

CMV serostatus

   

  D-/R-

4(4.9%)

5(4.8%)

NS

  D+/R-

3(3.7%)

4(3.85%)

 

  D-/R+

3(3.7%)

2(1.95%)

 

  D+/R+

71(87.7%)

93(89.4%)

 

Donor type

   

  Sibling donor

44(54.3%)

73 (70.2%)

P = 0.010

  Family donor

11 (13.6%)

3 (2.9%)

 

  Unrelated donor

26(32.1%)

28 (26.9%)

 

HLA typing

   

  HLA-identical

49 (60.5%)

79 (76.0%)

NS

  One allele mismatched

15 (18.5%)

15 (14.4%)

 

  Two alleles mismatched

8 (9.9%)

8 (7.7%)

 

  Three alleles mismatched

1 (1.2%)

1 (0.95%)

 

  Four alleles mismatched

6 (7.4%)

1 (0.95%)

 

  Five alleles mismatched

2 (2.5%)

0 (0.0%)

 

Stem cell source

   

  PBSCs

63 (77.8%)

90 (86.5%)

NS

  BM

1 (1.2%)

0 (0.0%)

 

  PBSCs + BM

17(21.0%)

14 (13.5%)

 

Median CD34+ cells per graft, ×106/kg (range)

8.8(5.4-11.9)

8.1(5.2-11.7)

NS

Conditioning

   

  TBI + CY

 

36 (34.6%)

NA

  Bu + CY

 

40 (38.5%)

 

  Bu + Flu

 

28(26.9%)

 

  Flu + Ara-c + TBI + CY

49 (60.5%)

  

  TBI + CY + VP-16

32 (39.5%)

  

GVHD prophylaxis

   

  CsA

4 (5.0%)

2 (1.9%)

NS

  CsA + MTX

33 (40.75%)

62 (59.6%)

 

  CsA + MTX + ATG

28 (34. 5%)

27 (26.0%)

 

  CsA + MTX + MMF

3 (3.7%)

2 (1.9%)

 

  CsA + MTX + ATG + MMF

13 (16.05%)

11 (10.6%)

 
  1. ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; ALAL = acute leukemia of ambiguous lineage; CML = chronic myelogenous leukemia; HD = Hodgkin’s disease; NHL = Non-Hodgkin’s lymphoma; MDS = myelodysplastic syndromes; BPDCN = blastic plasmacytoid dendritic cell neoplasm;CR = complete remission; CP = chronic phase; NR = not in CR; AP = accelerated phase; BC = blastic crisis; D = donor; R = recipient; PBSCs = peripheral blood stem cells; BM = bone marrow; TBI = total body irradiation; CY = cyclophosphamide; BU = busulfan; FLU = fludarabine; Ara-c = cytarabine; VP16 = etoposide; GVHD = graft-versus-host disease; CSA = cyclosporine A; MTX = methotrexate; ATG = antithymocyte globulin; MMF = mycophenolate mofetil; NS = not significant; NA = not applicable.
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us